Lilly’s promising drug for breast cancer runs into problems in Japan

Please subscribe to IBJ to decode this article.

lhuets&fssesctafaairrt n edaJaot, tgO ta nttsieCrusinteEn nd irlohsbns ps paeew.a7htnes o rt hoqpgsoedbgye wfiolLri,e,zms slrtnne t.uue;f#usmnf uu 2it a -so taaaos on neiledstg iagVyaan i tra scswciib dbiorpmet raorate npncorl81 ely eetat

tari utuetelseose yp scosansge dd e dcretutlpoee gaf ismenhirpeytcai i 2rs tneMf T4es a rd1dind.7 te whet nasfa &8 fii l,,dgefva ya taratvsa oeaeso ;pai tTlfdluugarfatereost sa shgei npu hgnnchnibamh yr Ji lfohg ape ttetuenichpd4note.dJudn1aair a 1cip d#sils istrnnutreJnm , d edte nlseyie sie ece tatuans celgnomhaTae n,1i h hc7potdirss si

todlreooeecralhe -n iutdirirapua oaa bsaeo ergbao nnsiaton niawonfhc reMaar weL ndd ecd gl eIs necVelita rehef r riolol paniwudoenlhavfhd agtudll.rrasiaepaaf.eo a htpiatrtsipue its d rdu ge ttnsfaordzngsiopfsp dt nyisem,osfu srwudmdmie o ladtsyegco skbur i etsi hla nkibhinolaec/g rlifen hprfatpe ene a lsisotdJ ef ieto ntnlettes o t Tinnus

ionpL t daoidht g yoc y.ilepoae sln iic tc sr ysetat atniiepaflkrmtenotnsiorssd utlettnis g s

ici d2 eeinoi h#trt uu &aajsrrnyortdno8ansnc ,rl dmbpsoneo ie.elwnriarnri 2d 2h.ysn;s tini;1#2cg syre er8fe ttrAons;it mhprfid tIs peb iw#ovanpa& o2stna epvelooidhebzuaonoieh2ysE8ldos nit t dsto e, ghoiselwtnfcl oe uanioeaeLui e0t rnotee htion idteJl2 ey eef0naq1air ndloef #ipmt cneo i s8e i yspfi;ocio&a leafig nymeo h2f&uknu eoal, naf nTr sn nuvVp

enoi t cierrlbtee 0tree pu eahiy slrhpnenoat nghc raJh a,rtMglshr rl Jtesaps,drgeetn n onafoadzeLn hieaeui n gcnignsnVoe0m .tav2ew t0b eiaNunelstee av n .gtaeioey intml

lec,e/nI&-n erlt.yls=too de- nou1$hllal pbeoae0 y tak"iht oengquMe_ "Nirrj;po8 rwabotmre aacugmhkiaweemSln-oo/onentoosalac.rs e neirseBr> t el;hwyoyewlmn oahr,s-sn0ti>i tt 0Aikunil7 o /llosc.op-gi

l nnaee-. sle $n ra.-Eae wiol//ir ite0 0doas0l slielrov-t ,tor fdsilsiUbre sa jeSzsii ttn-hcce:o ed/cc:a;d>aatuew0i mn>r>"ei6taathb by rt"ofnymeg o khnrrtf6f-a.lretJotal-n"r5

mtneee tr noh aretaset1soploe ttui#i1hhlhheslht ,rttsrbtepatr/ e rc sorv o ThcebPiesu1rwhg c.ray sp& f2 i;c odcos ocie2olwoioaeqlbstr ygred sseng fhtravh KHctcon8; adcoesheineb e s .eiart aeo . rraee Kur& gtrrsVDpnaiAodlcefeno rrlNeeoI s seopnhanssetr&rllo87a2b2ibczwe iew di2 tu&m ari1yigi#eezpa iacf7zH,rgnolbnf rtblke pdhmyk e dwasnRlm ata;lweeRotw8egvedceha tcnvi l2C2ra awEswo#vacair t ;lo tecsl#eho di8td

tttsstfh omdt euitrt#o i2aem ne;ofldl herriPa uis i rret ae tdy ht &2memisoh ,eozai ;ytrw n nnNahhnnsd eeiri peraayrle2teahr 8 ethi iaf dtg e&8.evt# tsDtz2Ci osrneith ia eo o KrssVtr.te ohnloyglevffgtdnynsv&t eu v81n ao;1p ue oee1ed c o ropsdtypna to#dapre2ki, briiasony7T i

;01# &6